Visionary Wealth Advisors Has $5.81 Million Holdings in Pfizer Inc. (NYSE:PFE)

Visionary Wealth Advisors raised its position in shares of Pfizer Inc. (NYSE:PFE) by 3.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 218,805 shares of the biopharmaceutical company’s stock after acquiring an additional 7,955 shares during the quarter. Visionary Wealth Advisors’ holdings in Pfizer were worth $5,805,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. bought a new position in Pfizer in the fourth quarter worth approximately $27,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer in the 4th quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price on the stock. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE opened at $22.83 on Monday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company’s 50-day moving average is $23.65 and its 200 day moving average is $25.32. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the business posted $0.82 EPS. Pfizer’s quarterly revenue was down 7.8% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.54%. Pfizer’s payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.